After a more than sevenfold YTD jump, Moderna (MRNA) fell nearly 10% in afternoon trading on Friday, becoming the biggest decliner in the S&P 500 (SP500) as investors await detailed results from a ...

Profit taking is hitting one of biotech’s hottest trades, and the selling is landing heaviest on the stock that ran the furthest. Moderna (NASDAQ:MRNA) stock is down 10% to $214.03 in morning trading, ...

Moderna (MRNA) stock has gained 282.6% over the past three months, outpacing a 4.1% return for the S&P 500. The shares ...

Moderna MRNA shares suffered a sharp reversal on Friday, falling close to 10% after a strong October rally had pushed the ...

According to TipRanks, Meacham is a 5-star analyst with an average return of 12.7% and a 56.16% success rate. Meacham covers the Healthcare sector, focusing on stocks such as Amgen, Bristol-Myers ...

The latest installment in BioPharma Dive’s data visualization-focused series includes a look at Moderna’s meteoric rise in 2026 and a sudden deal surge from Roche.

Stephen Hoge and Dean Li, at the STAT Summit, spoke of how Merck and Moderna will pair Keytruda with personalized mRNA ...

Moderna stock is a "Hold" due to persistent unprofitability, negative free cash flow, and a valuation highly dependent on ...

Healthcare is drawing fresh buying as money moves away from the market’s popular technology trade, and one messenger RNA ...

Moderna has surged more than 650% this year on cancer vaccine excitement, but analyst targets sit far below the current share ...

Moderna co-founder Noubar Afeyan urges regulation of commercial AI agents before launch, citing thalidomide as a warning for ...

Billionaire biotech mogul Noubar Afeyan has called for urgent regulation of artificial intelligence agents that tech firms ...